Conserved extended haplotypes of the major histocompatibility complex: further characterization

Since the complete sequencing of a human major histocompatibility complex (MHC) haplotype, interest in non-human leucocyte antigen (HLA) genes encoded in the MHC has been growing. Non-HLA genes, which outnumber the HLA genes, may contribute to or account for HLA and disease associations. Most information on non-HLA genes has been obtained in separate studies of individual loci. To comprehensively address polymorphisms of relevant non-HLA genes in 'conserved extended haplotypes' (CEH), we investigated 101 International Histocompatibility Workshop reference cell lines and nine additional anonymous samples representing all 37 unambiguously characterized CEHs at MICA, NFKBIL1, LTA, NCR3, AIF1, HSPA1A, HSPA1B, BF, NOTCH4 and a single nucleotide polymorphism (SNP) at HLA-DQA1 as well as MICA, NOTCH4, HSPA1B and all five tumour necrosis factor short tandem repeat (STR) polymorphisms. This work (1) provides an extensive catalogue of MHC polymorphisms in all CEHs, (2) unravels interrelationships between HLA and non-HLA haplotypical lineages, (3) resolves reported typing ambiguities and (4) describes haplospecific markers for a number of CEHs. Analysis also identified a DQA1 SNP and segments containing MHC class III polymorphisms that corresponded with class II (DRB3 and DRB4) lineages. These results portray the MHC where lineages containing non-HLA and HLA variants in linkage disequilibrium may operate in concert and can guide more thorough design and interpretation of HLA-disease relationships.     

The Adhesion Between a Microvillus-Bearing Cell and a Ligand-Coated Substrate: A Monte Carlo Study

In biology, specific cell adhesion is mediated by receptor–ligand interactions. Consequently, its strength correlates with the strength of single receptor–ligand bonds that can be measured with a variety of techniques. However, whether single receptor–ligand bonds are truly present in an experiment is often a concern. In this paper, we present a Monte Carlo simulation of the adhesion between a microvillus-bearing cell and a ligand-coated substrate. In the simulation, ligands were immobilized on the substrate either uniformly or in clusters of three and seven, while receptors were distributed uniformly on the microvillus tip and they moved randomly on the cellular surface. How ligand clustering affects the adhesion frequency and forward rate constant was studied. Other factors that were studied include receptor aggregation on the microvillus tip, ligand density, receptor density, contact time, and binding pocket size. In the case of uniformly distributed ligands, our simulation results agree well with those obtained from probabilistic analysis. We found that, even with clustered ligands on the substrate, most of the adhesion events were mediated by a single bond if the total adhesion frequency was less than 20%. Besides, ligand clustering decreased the total adhesion frequency and forward rate constant, but increased the single-bond adhesion frequency under comparable conditions. These findings should lend us some assistance in identifying single bonds in cell–substrate or cell–bead adhesion measurements and in illustrating some biological mechanisms that involve clustered ligands.     

苯并咪唑类对钩虫感染的疗效及虫群分布的观察

试点Ａ组和Ｂ组人群钩虫感染率分别为４９．２％和２８．２％，阳性人群平均ＥＰＧ分别为６２３．５和１９０．４。阳性者分别以２００ｍｇＭＢＺ＋１００ｍｇＡＢＺ一天两次（Ａ组）和一天三次（Ｂ组）治疗，阴转率分别为７５．３％和９７．９％，ＥＰＧ分别下降９２．７％和９７．９％。提示疗效受剂量和感染度影响，适当增加剂量和服药次数可取得更好疗效，宿主每天排虫结果表明两组每天排虫趋势相似，服药后第三天开始排虫，第四天排虫率最高。提示每天排虫率不依赖于剂量和疗程，而整个排虫过程却是时间依赖的。钩虫在人群中的分布高度聚集、符合负二项分布，参数Ｋ值分别为０．２８９（Ａ组）和０．２０６（Ｂ组）。以平均虫荷为感染度的年龄－感染度曲线随年龄增长而上升。     

Interleukin-17D regulates group 3 innate lymphoid cell function through its receptor CD93

1. Download : Download high-res image (175KB)
2. Download : Download full-size image

     

纳曲酮对移植排异反应的抑制作用

以小鼠心肌组织异位移植和混合淋巴细胞反应为整体和离体模型，观察了阿片受体阻断剂纳曲酮对移植排异反应的影响。结果显示：给动物从术前开始腹腔注射纳曲酮共１０天（每日二次，每次５ｍｇ／ｋｇ）可明显延长移植心肌组织的存活时间；加入纳曲酮（１０－４～１０－８ｍｏｌ／Ｌ）对混合淋巴细胞反应有抑制作用并呈量效关系。同时还观察到，给正常小鼠腹腔注射纳曲酮３天以上，可引起动物脾细胞由ＣｏｎＡ诱导的淋巴细胞转化反应受抑制。以上结果说明纳曲酮可抑制移植排异反应，此作用有可能是通过阻断内源性阿片肽所致。     

Role of tissue transglutaminase type 2 in calbindin-D28k interaction with ataxin-1

Spinocerebellar ataxia-1 (SCA1) is caused by the expansion of a polyglutamine repeats within the disease protein, ataxin-1. The mutant ataxin-1 precipitates as large intranuclear aggregates in the affected neurons. These aggregates may protect neurons from mutant protein and/or trigger neuronal degeneration by encouraging recruitment of other essential proteins. Our previous studies have shown that calcium binding protein calbindin-D28k (CaB) associated with SCAl pathogenesis is recruited to ataxin-l aggregates in Purkinje cells of SCAl mice. Since our recent findings suggest that tissue transglutaminase 2 (TG2) may be involved in crosslinking and aggregation of ataxin-l, the present study was initiated to determine if TG2 has any role in CaB-ataxin-l interaction. The guinea pig TG2 covalently crosslinked purified rat brain CaB. Time dependent progressive increase in aggregation produced large multimers, which stayed on top of the gel. CaB interaction with ataxin-l was studied using HeLa cell lysates expressing GFP and GFP tagged ataxin-l with normal and expanded polyglutamine repeats (Q2, Q30 and Q82). The reaction products were analyzed by Western blots using anti-polyglutamine, CaB or GFP antibodies. CaB interacted with ataxin-1 independent of TG2 as the protein-protein crosslinker DSS stabilized CaB-ataxin-l complex. TG2 crosslinked CaB preferentially with Q82 ataxin-1. The crosslinking was inhibited with EGTA or TG2 inhibitor cystamine. The present data indicate that CaB may be a TG2 substrate. In addition, aggregates of mutant ataxin-l may recruit CaB via TG2 mediated covalent crosslinking, further supporting the argument that ataxin-l aggregates may be toxic to neurons.     

Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate

Mood stabilizing drugs lithium and valproate are the most commonly used treatments for bipolar disorder. Previous studies in our laboratory indicate that chronic treatment with lithium and valproate inhibits oxidative damage in primary cultured rat cerebral cortical cells. Glutathione, as the major antioxidant in the brain, plays a key role in defending against oxidative damage. The purpose of this study was to determine the role of glutathione in the neuroprotective effects of lithium and valproate against oxidative damage. We found that chronic treatment with lithium and valproate inhibited reactive oxygen metabolite H(2)O(2)-induced cell death in primary cultured rat cerebral cortical cells, while buthionine sulfoximine, an inhibitor of glutathione rate-limiting synthesis enzyme glutamate-cysteine ligase, reduced the neuroprotective effect of lithium and valproate against H(2)O(2)-induced cell death. Further, we found that chronic treatment with lithium and valproate increased glutathione levels in primary cultured rat cerebral cortical cells and that the effects of lithium and valproate on glutathione levels were dose-dependent in human neuroblastoma SH-SY5Y cells. Chronic treatment with lithium and valproate also increased the expression of glutamate-cysteine ligase in both rat cerebral cortical cells and SH-SY5Y cells. In addition, chronic treatment with other mood stabilizing drugs lamotrigine and carbamazepine, but not antidepressants desipramine and fluoxetine, increased both glutathione levels and the expression of glutamate-cysteine ligase in SH-SY5Y cells. These results suggest that glutathione plays an important role in the neuroprotective effects of lithium and valproate, and that glutathione may be a common target for mood stabilizing drugs.     

The vitamin D content of fortified milk and infant formula.

BACKGROUND. The fortification of milk and infant formula with vitamin D has had an important role in eliminating rickets in children and osteomalacia in adults. A recent outbreak of vitamin D intoxication caused by drinking milk fortified with excess vitamin D has led to questions about the level of vitamin D in milk from other producers. METHODS. We used high-performance liquid chromatography to measure vitamin D in samples of 13 brands of milk with various fat contents and 5 brands of infant formula purchased at random from local supermarkets in five Eastern states. RESULTS. Only 12 (29 percent) of the 42 samples of the 13 brands of milk and none of the 10 samples of the 5 brands of infant formula contained 80 to 120 percent of the amount of vitamin D stated on the label. Twenty-six of the 42 milk samples (62 percent) contained less than 80 percent of the amount claimed on the label. No vitamin D was detected in 3 of the 14 samples of skim milk tested (lower limit of assay, 4.7 IU per quart [5.0 IU per liter]). One milk sample labeled as containing vitamin D2 (ergocalciferol) contained vitamin D3 (cholecalciferol). Seven of the 10 samples of infant formula contained more than 200 percent of the amount stated on the label; the sample with the highest concentration contained 419 percent of the stated amount. None of the samples of infant formula contained less than the amount stated. CONCLUSIONS. Milk and infant-formula preparations rarely contain the amount of vitamin D stated on the label and may be either underfortified or overfortified. Since both underfortification and overfortification are hazardous, better monitoring of the fortification process is needed.